ArticleClinical and vaccine immunology : CVI2008
Reproducibility of QuantiFERON-TB gold in-tube assay.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Pooled it
- Trial
- Trial
- Enhancing the interferon-γ release assay through omission of nil and mitogen values.Respiratory research · 2023Article
- High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Article
- Tuberculosis Infection Screening in 5468 Italian Healthcare Students: Investigation of a Borderline Zone Value for the QFT-Test.International journal of environmental research and public health · 2020Article
- The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2017Article
- QFT-Plus: a plus in variability? - Evaluation of new generation IGRA in serial testing of students with a migration background in Germany.Journal of occupational medicine and toxicology (London, England) · 2017Article
- Interferon Gamma Release Assays for Latent Tuberculosis: What Are the Sources of Variability?Journal of clinical microbiology · 2016Review
- Antigen-Specific IFN-Journal of immunology research · 2016Article
- Serial interferon-gamma release assays for latent tuberculosis in dialysis patients with end stage renal disease in a Korean population.BMC infectious diseases · 2015Article
- QuantiFERON-TB Gold and Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Children.Iranian journal of medical sciences · 2015Article
- Tuberculosis: medico-legal aspects.Mediterranean journal of hematology and infectious diseases · 2014Review
- Variability of the QuantiFERON®-TB gold in-tube test using automated and manual methods.PloS one · 2014Article
- Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants.PloS one · 2014Article
- The immune response to tuberculosis infection in the setting of Helicobacter pylori and helminth infections.Epidemiology and infection · 2013Article
- Test variability of the QuantiFERON-TB gold in-tube assay in clinical practice.American journal of respiratory and critical care medicine · 2013Article
- Interferon-Gamma Release Assays versus Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection: An Overview of the Evidence.Pulmonary medicine · 2013Article
- Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review.Journal of occupational medicine and toxicology (London, England) · 2012Article
- Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists.Arthritis research & therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Studies are needed to characterize the reproducibility of QuantiFERON-TB Gold (QFT-G) for targeted U.S. screening populations. Members of northern California households were tested with the QFT-G in-tube assay (QFT-G-IT) at two home visits 3 months apart. Reproducibility and agreement with the tuberculin skin test (TST) were assessed. Monte Carlo simulation was used to evaluate the role of test-related error. Of 63 individuals (49 adults and 14 children) completing QFT-G-IT at both time points, 79% were foreign-born (98% from Latin America) and 68% reported Mycobacterium bovis BCG vaccination. At the baseline visit, 23 (37%) were TST positive and 15 (24%) were QFT-G-IT positive (kappa = 0.48 [+/- 0.11]). At 3 months, 3/48 (6.3%; 95% confidence interval [95CI], 2 to 17) of those initially QFT-G-IT negative converted, and 5/15 (33%; 95CI, 15 to 58) of those initially QFT-G-IT positive reverted. Among the 8 individuals with inconsistent QFT-G-IT results, the maximum gamma interferon response at either visit was 0.68 IU/ml versus means of 4.99 (+/- 3.74) and 6.95 (+/- 5.6) for 10 persistent positives at the first and second visits, respectively. Expected false-reversion and -conversion rates were 32% (90CI, 25 to 39%) and 6.95% (90CI, 4.6 to 9.8%) when the sensitivity and specificity were assumed to average 70% and 98%, respectively. Transient responses to QFT-G-IT are common, and low positive results need to be interpreted with caution. Further studies are needed to characterize the predictive value of the test for U.S. foreign-born and other targeted screening populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.